Creating novel solutions
to treat patients with chronic
metabolic diseases.

Pipeline

Our focus in the clinic is on advancing our lead candidate HTD1801 in chronic metabolic diseases. Based on its dual mechanism of action we are particularly focused on diseases driven by insulin resistance and chronic inflammation. In addition to our lead candidate, we have a growing discovery portfolio.

Man peering through microscope
Obesity
MASH
T2DM
Hyperlipidemia
Metabolic
Syndrome
Insulin Resistance
&
Chronic Inflammation

Our Approach

HighTide Therapeutics’ mission is to identify unmet needs in inter-related chronic metabolic diseases, with a particular focus on cardiovascular-renal-metabolic (CKM) diseases, and to translate those needs into innovative therapeutic solutions.